Curis Inc. (CUS0)

Overview

Curis, Inc. is at the forefront of biotechnological research, primarily focusing on innovating drug candidates aimed at combatting various forms of human cancer. The company operates within the United States, leveraging cutting-edge science to push the boundaries of medical treatments. Since its inception in 2000, Curis has committed to exploring new pathways for treating cancer, collaborating with leaders in the pharmaceutical industry to enhance its research capabilities and extend its reach in providing advanced care. With a strategic base in Lexington, Massachusetts, Curis continues to evolve its portfolio of novel treatments, aligning with both national and international standards of healthcare innovation.

Products and Services

• Emavusertib

  An oral small molecule IRAK4 kinase inhibitor currently in a Phase 1/2 trial. This drug candidate is designed for patients with relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes. By targeting the IRAK4 kinase, Emavusertib represents a novel approach to disrupting cancer cell signaling pathways specifically associated with these conditions.

• Fimepinostat

  This oral drug combines dual inhibition mechanisms against HDAC and PI3K enzymes, making it a potent candidate for treating patients with relapsed or refractory diffuse large B-cell lymphoma. Fimepinostat’s unique action on two critical enzymes involved in cancer cell growth and survival offers a promising therapeutic option for individuals battling this aggressive form of lymphoma.

• CA-170

  A pioneering oral, small molecule antagonist that targets PD-L1 and VISTA pathways. CA-170 exhibits potential in providing a new treatment avenue for patients by leveraging the body's immune system to combat cancer cells more effectively. By selectively inhibiting these pathways, CA-170 aims to restore the immune system's ability to recognize and eliminate cancer cells.

• CA-327

  An oral, small molecule antagonist targeting the PD-L1 and TIM3 pathways. CA-327 is designed to hinder the mechanisms that enable cancer cells to evade the immune response. This drug candidate represents a multi-targeted approach to enhancing the immune system's capability to fight against cancer, offering hope for improved outcomes in treatment-resistant cases.

• Erivedge Collaboration

  Through its partnership with Genentech Inc. and F. Hoffmann-La Roche Ltd, Curis has contributed to the commercialization of Erivedge, an orally-administered small molecule antagonist of the hedgehog signaling pathway. This novel therapy is approved for the treatment of advanced basal cell carcinoma (BCC), representing a significant advancement in treating this form of skin cancer.

• Aurigene Discovery Technologies Limited Collaboration

  Curis’s collaboration with Aurigene Discovery Technologies Limited underscores its commitment to immuno-oncology and precision oncology. This strategic partnership focuses on the discovery, development, and commercialization of small molecule compounds, including the development of emavusertib and the licensing of four programs under the agreement. This collaborative effort aims to expand Curis’s portfolio and enhance its ability to address a wider range of cancers with novel therapies.